Drug
Vicriviroc clinical trials
Also written SCH 417690.
- studies test it
- 11
- open now
- 0
- in phase 3
- 3
- first study started
- 2004
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
11 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 7
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 2
Merck Sharp & Dohme LLC (9) · National Institute of Allergy and Infectious Diseases (NIAID) (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vicriviroc is read from its arms, and is right about nine times in ten.
Testing it · 11
- Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)CompletedPhase 2Merck Sharp & Dohme LLCNCT03631407Written as Vicriviroc
- Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00474370Written as Vicriviroc
- Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and AdolescentsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00766597Written as Vicriviroc
- Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected PatientsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00082498Written as SCH-D (vicriviroc)
- Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)CompletedPhase 2Merck Sharp & Dohme LLCNCT00243230Written as Vicriviroc 30 mg
- Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)CompletedPhase 2Merck Sharp & Dohme LLCNCT00686829Written as Vicriviroc maleate
- Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285WithdrawnPhase 3Merck Sharp & Dohme LLCNCT00243568Written as Vicriviroc
- Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)CompletedPhase 2Merck Sharp & Dohme LLCNCT00551330Written as Vicriviroc
- Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)CompletedPhase 3Merck Sharp & Dohme LLCNCT00523211Written as Vicriviroc
- Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)CompletedPhase 1Merck Sharp & Dohme LLCNCT00632073Written as Vicriviroc
- Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)CompletedPhase 2Merck Sharp & Dohme LLCNCT00551018Written as Vicriviroc
Codes
What other systems call vicriviroc · ClinicalTrials.gg INT004651
- MeSH (NLM) C486781vicrivirocOne source NLM
- UNII (FDA) TL515DW4QSVICRIVIROCConfirmed FDA, NLM, Wikidata
- Wikidata Q3557001vicrivirocConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73589VicrivirocOne source FDA
- DrugBank DB06652One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C486781 | vicriviroc | One source NLM |
| UNII (FDA) | TL515DW4QS | VICRIVIROC | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3557001 | vicriviroc | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73589 | Vicriviroc | One source FDA |
| DrugBank | DB06652 | — | One source Wikidata |
Also registered as vicriviroc maleate (UNII EP3QG127N9).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.